Causes of death in patients with Non-alcoholic Fatty Liver Disease (NAFLD), alcoholic liver disease and chronic viral Hepatitis B and C
- PMID: 34800721
- DOI: 10.1016/j.aohep.2021.100556
Causes of death in patients with Non-alcoholic Fatty Liver Disease (NAFLD), alcoholic liver disease and chronic viral Hepatitis B and C
Abstract
Introduction and objectives: Cause of mortality in patients with chronic liver diseases (CLDs) may differ based on underlying etiology of liver disease. Our aim was to assess different causes of death in patients with the most common types of CLD using a national database from the United States.
Materials and methods: Death data from 2008 and 2018 from the National Vital Statistics System (NVSS) by the National Center for Health Statistics (NCHS) were used. The rank of cause-of-death for each etiology of CLDs was assessed. Causes of death were classified by the ICD-10 codes. Liver-related deaths included liver cancer, cirrhosis and CLDs.
Results: Among a total of 2,826,531 deaths in 2018, there were 85,807 (3.04%) with underlying CLD (mean age at death 63.0 years, 63.8% male, 70.8% white). Liver-related mortality was the leading cause of death for all types of CLD [45.8% in non-alcoholic fatty liver disease (NAFLD), 53.0% in chronic hepatitis C (CHC), 57.8% in chronic hepatitis B (CHB), 81.8% in alcoholic liver disease (ALD)]. This was followed by death from cardiac causes (NAFLD 10.3%, CHC 9.1%, CHB 4.6%, ALD 4.2%) and extrahepatic cancer (NAFLD 7.0%, CHC 11.9%, CHB 14.9%, ALD 2.1%). Although liver cancer was the leading cause of cancer death, lung, colorectal and pancreatic cancer were also common causes of cancer death.
Conclusions: Among deceased patients with CLD, underlying liver disease was the leading cause of death. Among solid cancers, liver cancer was the leading cause of cancer-related mortality.
Keywords: Alcoholic liver disease; Chronic hepatitis B; Chronic hepatitis C; Cirrhosis; Non-alcoholic fatty liver disease; Outcome; Trend.
Copyright © 2021 Fundación Clínica Médica Sur, A.C. Published by Elsevier España, S.L.U. All rights reserved.
Conflict of interest statement
Conflicts of interest Dr. Younossi is a consultant to BMS, Gilead, AbbVie, Novo Nordisk, Merck, Quest Diagnostics, Viking, Tern Pharmaceuticals, Siemens and Intercept. Dr. Alqahtani consults for and received grants from AbbVie, Bristol-Meyers Squibb, Gilead, Janssen, and Merck. All other authors have no conflict of interest to disclose.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
